SXI

Standex is mid-transformation, not mid-compounding. FY2025 revenue grew 9.6% to $790M almost entirely on the back of an aggressive M&A spree disclosed in MD&A — Amran/Narayan (~$467.5M EV, closed Oct 2024), Custom Biogenic Systems (Nov 2024), Nascent (Nov 2024) and McStarlite (Feb 2025). Strip out those, and the organic story is the same one the FY2021–FY2024 series shows: revenue oscillating in a tight $720–$741M band with no real underlying growth. Worse, on a reported basis the deals destroyed near-term earnings power: net income fell 23.7% to $55.8M, EPS dropped 24.4% to $4.64, operating income slipped 8%, and operating cash flow fell 24.9% to $69.6M.

The balance sheet is the bigger tell. Long-term debt jumped 271% to $553M to fund the deal stack, cash drew down 32% to $105M, and total assets ballooned 55.9% — i.e., the asset base inflated faster than earnings, dragging ROE to a pedestrian 7.8%. Management itself flags the dependency in the Risk Factors: 'We rely on our revolving credit facility... availability is dependent upon our compliance with the covenants... Violation of those covenants could result in our lenders restricting or terminating our borrowing ability... or trigger an event of default.' That risk wasn't material at FY2024 leverage; at FY2025 leverage it is.